3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Anus Neoplasms
1
Interventions
Methods
3
Trastuzumab
2
Radiotherapy
2
Early Intervention, Educational
2
Behavior Therapy
2
tivozanib
1
tipifarnib
1
nanocis
1
entinostat
1
atezolizumab
1
Technetium-99
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Ritonavir
1
Quality of Life
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Interviews as Topic
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Infracyanine green
1
Indocyanine Green
1
Indinavir
1
Immunotherapy
1
Immunohistochemistry
1
Hysterectomy
1
Gene Rearrangement
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
Technetium-99
×
Breast
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled